Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Roy S. Herbst, Paul Baas, Jose Luis Perez-Gracia, Enriqueta Felip, Dong-Wan Kim, Ji-Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary J. Fidler, Veerle Surmont, Gilberto Castro, Marcelo Garrido, Yue Shentu, Marisa Dolled-Filhart, Ellie Im, Edward B. Garon
Institutions: Yale Cancer Center, Yale University, The Netherlands Cancer Institute, Clinica Universidad de Navarra, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Seoul National University Hospital, National Cancer Center, Mayo Clinic, CHA University Bundang Medical Center, CHA University, Centre François Baclesse, Samsung Medical Center, Sungkyunkwan University, Hospital de Sant Pau, Rush University Medical Center, Ghent University Hospital, Instituto do Câncer do Estado de São Paulo, Pontificia Universidad Católica de Chile, Merck & Co., Inc., Rahway, NJ, USA (United States), University of California, Los Angeles
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2531661570